Prot. R5459-RT-1944: A Dose Escalation and Proof-Of-Concept Study of REGN5459 or REGN5458 (BCMA × CD3 Bispecific Antibodies) for Desensitization of Chronic Kidney Disease Patients in Need of Kidney Transplantation Who Are Highly Sensitized to Human Leukoc

Project: Research project

Project Details

Effective start/end date1/30/231/30/26


  • Parexel (Prot. R5459-RT-1944 // Prot. R5459-RT-1944)
  • Regeneron Pharmaceuticals, Inc. (Prot. R5459-RT-1944 // Prot. R5459-RT-1944)